For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AZC865. CME credit will be available until 19 June 2026.
Navigating the Layers of Complexity in R/R B-Cell Cancers: From Clinical Prognosis to Emerging Therapeutic Prospects in CLL/SLL, MCL, and DLBCL
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.
Disclosure information is available at the beginning of the video presentation.
View all episodes
By PVI, PeerView Institute for Medical Education
4.5
22 ratings
For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AZC865. CME credit will be available until 19 June 2026.
Navigating the Layers of Complexity in R/R B-Cell Cancers: From Clinical Prognosis to Emerging Therapeutic Prospects in CLL/SLL, MCL, and DLBCL
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.
Disclosure information is available at the beginning of the video presentation.
28 Listeners
10 Listeners
5 Listeners
10 Listeners
4 Listeners
2 Listeners
4 Listeners
2 Listeners
3 Listeners
5 Listeners
5 Listeners
2 Listeners
0 Listeners
9 Listeners
2 Listeners
12 Listeners
4 Listeners
3 Listeners
5 Listeners